[Pharmacotherapy for obesity].
Obesity is a chronic condition, which is why pharmacotherapy can be considered, if lifestyle modification (hypocaloric diet/exercise) does not result in a weight loss of at least 5%. Pharmacotherapy is indicated, if an individual has a BMI > 30 kg/m2or a BMI > 27 kg/m2and concomitant disease (e.g. Type 2 diabetes), and can be liraglutide (3 mg) or orlistat (120 mg/60 mg). Choice of treatment must be based on patient preferences and clinical situation, side effects, contraindications and financial considerations. Weight loss of < 5% (about 4-5 kg) after 12 weeks should lead to cessation of the treatment.
jensbruu@rm.dk.
Jens Meldgaard
JM
Bruun
D019440:Anti-Obesity Agents / Q000627:therapeutic use*; D015992:Body Mass Index; D003924:Diabetes Mellitus, Type 2 / Q000150:complications / Q000188:drug therapy; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D007783:Lactones / Q000627:therapeutic use*; D000069450:Liraglutide / Q000627:therapeutic use*; D009765:Obesity / Q000150:complications / Q000188:drug therapy*; D000077403:Orlistat; D015431:Weight Loss / Q000187:drug effects
D019440:Anti-Obesity Agents; D007004:Hypoglycemic Agents; D007783:Lactones; D000069450:Liraglutide; D000077403:Orlistat